Genetic alterations in hepatocellular carcinomas: association between loss of chromosome 4q and p53 gene mutations by Rashid, A et al.
Hepatocellular carcinoma (HCC) is one of the most common
causes of cancer death worldwide (Yu and Chen, 1994). The
incidence of HCC shows considerable geographical variation, and
there is a very high incidence of HCC in China, sub-Saharan
Africa and Southeast Asia but a low incidence in North America
and Europe. Epidemiological studies in high-risk populations have
identified chronic hepatitis B virus (HBV) and chronic hepatitis C
virus (HCV) infections as well as dietary exposure to aflatoxin B1
(AFB1) as major factors in the aetiology of this disease (Groopman
et al, 1996). Glutathione S-transferase M1 (GSTM1) and micro-
somal epoxide hydrolase are implicated in detoxification of AFB1,
and increased frequency of mutant alleles is present in patients
with HCC (McGlynn et al, 1995). In the People’s Republic of
China, Qidong has high exposure to aflatoxin while Shanghai has
intermediate exposure (Qian et al, 1994).
Mutations of the p53 tumour suppressor gene are common in
HCC, and a distinct pattern of mutations in this gene has been
described. HCC from China and sub-Saharan Africa, areas with a
high incidence of chronic HBV infection and dietary exposure to
AFB1, have a G–T transversion at codon 249 of the p53 gene that
is present in 10–50% of tumours (Bressac et al, 1991; Hsu et al,
1991; Ozturk et al, 1991; Coursaget et al, 1993). The biology of
this mutant p53 gene product has been characterized in a trans-
genic mouse model (Ueda et al, 1995), in murine and human hepa-
tocyte cell lines (Mace et al, 1991; Dumenco et al, 1995), and in
human hepatoma cell lines (Aguilar et al, 1993; Ponchel et al,
1994). In HCC from areas with low dietary exposure to AFB1, p53
mutations are seen at a much lower frequency, and a broader spec-
trum of mutations which do not affect a particular codon is evident
(Nose et al, 1993; Hayashi et al, 1995; Kubicka et al, 1995; Shi et
al, 1995). p53 overexpression due to prolonged half-life of many
mutated p53 gene products and loss of heterozygosity (LOH) of
17p are also present in HCCs with a p53 mutation (Nose et al,
1993; Hsu et al, 1994; Bourdon et al, 1995; Yumoto et al, 1995). In
HCCs developing in a person with chronic HBV infection,
hepatitis B x antigen (HBxAg), a HBV-encoded protein, may bind
p53 protein and cause functional inactivation of p53 (Greenblatt et
al, 1997). Thus, gene–chemical, gene–virus and chemical–virus
interactions may have great significance in the early onset and
rapid lethality of HCC.
Many chromosomal aberrations are reported frequently in
HCCs, including LOH of chromosome 1p, 4p, 4q, 6q, 8p, 9p, 11p,
13q, 16p, 17p and 22q by cytogenetics, restriction length fragment
polymorphism (RFLP) analysis and microsatellite analysis (Wang
et al, 1988; Buetow et al, 1989; Tsuda et al, 1990; Zhang et al,
1990, 1994; Fujimori et al, 1991; Simon et al, 1991; Walker et al,
1991; Emi et al, 1992; Slagle et al, 1993; Takahashi et al, 1993;
Yeh et al, 1994, 1996; De Suza et al, 1995; Nasarek et al, 1995;
Kuroki et al, 1995a, 1995b; Yumoto et al, 1995; Chen et al, 1996;
Leon et al, 1996; Becker et al, 1996; Boige et al, 1997; Marchio et
al, 1997; Nagai et al, 1997). Previous studies have shown an asso-
ciation between p53 gene mutations, LOH, metabolic enzyme
polymorphisms, or hepatitis viruses in HCCs from Shanghai and
Qidong, the People’s Republic of China, representing areas of
intermediate and high exposure to aflatoxin, respectively. The
purpose of this study was to explore interactions among multiple
aetiological and genetic variables.
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Summary The major risk factors for hepatocellular carcinomas (HCC) in high incidence areas include infection with hepatitis B and C viruses
(HBV, HCV) and exposure to aflatoxin. Genetic alterations in 24 liver resection specimens from Shanghai and Qidong were studied. Hepatitis
B virus was integrated in all patient samples, and a null phenotype for the GSTM1 enzyme was present in 63% of patients. Alteration of p53
was present in 95% (23/24) of cases: mutations of the p53 gene in 12 HCC, p53 overexpression in 13 and loss of heterozygosity (LOH) of
chromosome 17p in 17. All seven HCCs with a p53 mutation from Qidong and three of five from Shanghai had the aflatoxin-associated point
mutation with a G to T transversion at codon 249, position 3. No HCC had microsatellite instability. LOH of chromosome 4q, 1p, 16q and 13q
was present in 50%, 46%, 42% and 38%, respectively, and 4q was preferentially lost in HCCs containing a p53 mutation: LOH of 4q was
present in 75% (9/12) of HCC with, but only 25% (3/12) of HCC without, a p53 gene mutation (P = 0.01). These data indicate a possible
interaction between p53 gene mutation and 4q loss in the pathogenesis of HCC.
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Case material
Fresh tissue was collected from patients diagnosed with HCC
undergoing hepatic resection in Shanghai (n = 10) and Qidong
(n = 14), People’s Republic of China (Table 1). Neoplastic and
non-neoplastic liver tissue were frozen in liquid nitrogen and kept
at –70°C until processing.
Histopathological examination
Representative sections of neoplastic and non-neoplastic frozen
tissues were thawed, fixed in formalin and embedded in paraffin.
Standard haematoxylin and eosin and Masson’s trichrome sections
were reviewed by one of us (AR). Each non-neoplastic liver tissue
was scored for chronic hepatitis (defined by lobular and portal
chronic inflammation, hepatocyte degeneration and fibrosis) and
cirrhosis. Each HCC was scored for tumour differentiation.
Immunohistochemistry for hepatitis B surface and core
antigens and hepatitis C virus antigen
Immunohistochemistry was performed on thawed, formalin-fixed,
paraffin-embedded tissue using a standard avidin–biotin complex
(ABC) immunohistochemical technique after antigen retrieval by
a heat-induced epitope retrieval method (Bankfalvi et al, 1994).
The primary antibodies used in the present study were hepatitis B
surface antigen (HBsAg; Zymed Industries Inc., San Fransisco,
CA, USA) at 1:1000 dilution, hepatitis B core antigen (HBcAg;
DAKO Corporation, Carpinteria, CA, USA) at 1:10 000 dilution,
HCV (Signet Laboratories, Dedham, MA, USA) at 1:100 dilution
and p53 (D07, DAKO Corporation, Carpinteria, CA, USA) at
1:100 dilution. Immunohistochemistry was performed on 5-mm
sections on Probe-on Plus slides (Fisher Scientific), which were
mounted and baked for 20 min at 60°C. Sections were reacted with
primary antibody for 2 h. As a negative control, adjacent sections
were treated with isotype-matched antibody using equivalent
conditions. Secondary reagents were obtained from the Vector
Elite ABC kit (Vector, Burlingham, CA, USA) and diaminobenzi-
dine was used as chromogen with light haematoxylin counterstain.
DNA preparation
Genomic DNA was extracted from microdissected neoplastic and
non-neoplastic frozen tissue using a commercial kit according to
the manufacturer’s instructions (QIAamp tissue kit, Qiagen Inc.,
Valencia, CA, USA).
PCR amplification for HBsAg, HBxAg and GSTM1
genes
Integration of HBV was determined by PCR amplifications of
HBsAg and HBxAg gene segments as described (Hsu et al, 1993)
from genomic DNA prepared from the neoplastic and non-
neoplastic tissue. GSTM1 was genotyped by two separate poly-
merase chain reaction (PCR) amplifications of genomic DNA
from non-neoplastic liver tissue to amplify a 273 base pair
segment of exons 4 and 5 (Comstock et al, 1990) and a 650 base
pair segment of exons 3–5 using oligonucleotides as described
previously (Brockmoller et al, 1993). The PCR products were
analysed on a 1.5% agarose gel. For each assay, a band represented
the presence of DNA encoding a viral protein or an active enzyme,
whereas absence of a band indicated absence of the DNA segment
encoding a viral protein or the presence of a disabling deletion
mutation of enzyme. Null genotype, represented by deletion of the
GSTM1 locus, was discriminated from the presence of GSTM1 in
the hemizygous or homozygous state.
Sequencing of epoxide hydrolase and p53 genes
A segment of epoxide hydrolase exon 3 was amplified by a PCR
reaction of non-neoplastic genomic DNA using the oligonucleo-
tides 5¢-CCC CAC CTT TGG AGG ACA GC-3¢, and 5¢-CCC
TTC AAT CTT AGT CTT G-3¢. The PCR product was sequenced
using the oligonucleotide 5¢-GTC ATC TCC TAC TGG GGG-3¢.
Exons 2–9 of p53 were sequenced as described previously
(Redston et al, 1994). p53 mutations were confirmed by a repeat
PCR amplification and sequencing, and non-neoplastic DNA was
sequenced to rule out a germline p53 mutation.
Microsatellite markers and LOH
Microsatellite markers were obtained from Research Genetics
(Huntsville, AL, USA). LOH was analysed by PCR amplification
of dinucleotide repeats or tandem repeats (Table 2) present on
chromosomes 1p, 4q, 13q, 16q and 17p. A PCR-based microsatel-
lite-repeat assay was carried out in 96-well plates for 38 cycles per
minute using PCR Master (Boehringer Mannheim, GamH,
Germany), as described previously (Rashid and Hamilton, 1997).
Loss of a chromosomal marker was considered to be present when
the PCR assay showed absence or more than 50% loss of intensity
of a heterozygous band from a tumour sample as compared with
the corresponding non-tumour sample. Complete or partial loss of
the chromosomal arm was determined from the pattern of markers
with LOH. Fractional allelic loss (FAL) was calculated for each
tumour as percentage of microsatellite markers lost among infor-
mative markers.
Statistical analysis
Statistical significance was calculated by Fisher’s exact test using
True Epistat (Epistat Services, Richardson, TX, USA). All
P-values reported are two-sided.
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Figure 1 Abnormalities of p53 gene in hepatocellular carcinomas. Mutation
of the p53 gene by DNA sequencing, loss of heterozygosity (LOH) of
microsatellite markers on the short arm of chromosome 17 and
overexpression of p53 by immunohistochemistryRESULTS
Histopathological assessment
Fifty-eight per cent (14/24) of HCCs were moderately differenti-
ated and 42% (10/24) were poorly differentiated (Table 1).
Cirrhosis was present in non-neoplastic liver in 71% (17/24) of
patients, and chronic hepatitis was present in all cases.
Hepatitis B and C virus status
DNA segments encoding HBsAg and HBxAg could be amplified
from the neoplastic and non-neoplastic DNA from all 24 cases
of HCCs, indicating integration of viral DNA (Table 1).
Immunohistochemistry for HBsAg was positive in non-neoplastic
liver in 79% (17/24) of cases, and in 37% (7/24) of HCCs (Table
1). Immunohistochemistry for HBcAg was positive in only two
non-neoplastic liver samples, and immunohistochemistry for
hepatitis C virus antigen was negative in all neoplastic and non-
neoplastic samples.
GSTM1 and epoxide hydrolase genotype
Null genotype for GSTM1 was present in 63% (15/24) of patients
(Table 1) versus 41% in a control population in Shanghai in a
previous study (McGlynn et al, 1995). The remaining nine (37%)
patients had at least one copy of the functional enzyme.
Fifty-four per cent (13/24) of patients had an abnormal genotype
of epoxide hydrolase (Table 1). The wild-type sequence with
homozygous tyrosine at codon 113 was replaced by a homozygous
histidine, representing a polymorphic phenotype with less active
enzyme, in 29% (7/24) of patients, and a heterozygous
histidine/tyrosine was present in 25% (6/24, Table 1). These
frequencies were not statistically different from a control popula-
tion in Shanghai: in a previous study (McGlynn et al, 1995), a
homozygous histidine at codon 113 was present in 26% of control
population in Shanghai, a heterozygous histidine/tyrosine in 40%,
and a homozygous tyrosine wild-type in 34% respectively.
Six patients had mutant alleles in both GSTM1 and epoxide
hydrolase. Ninety-two per cent (22/24) of patients had a null
GSTM1 genotype and/or had a histidine in epoxide hydrolase
gene.
Mutations of p53 gene, overexpression of p53 gene
product by immunohistochemistry and LOH of
chromosome 17p
Abnormality of p53 was the most common alteration in this set of
HCCs, present in 95% (23/24) of cases as determined by genomic
sequencing of exons 2–9, overexpression of p53 by immunohisto-
chemistry, or LOH of chromosome 17 p (Figure 1). Fifty per cent
(12/24) of HCCs had mutations in exons 2–9 of the p53 gene
(Table 1). All seven HCCs with a p53 mutation from Qidong and
three of five HCCs from Shanghai had point mutations with a G to
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Table 1 Histopathological features, hepatitis B virus status, alterations of p53 gene, and polymorphism of aflatoxin enzymes in HCC
Tumor no. Cirrhosis Differentiation PCR HBsAg HBcAg p53 p53 sequencing GSTM1 null Epoxide
of HCC HBsAg/ IHCa IHC IHC amino acid (nucleotides) phenotypeb hydrolasec
HbxAg
Shanghai
1C-221 – Moderate + N+ – + 174 Arg-Trp (AGG-TGG) – H/H
1C-223 – Moderate + – – – Wild-type – Y/Y
1C-224 – Moderate + T/N + – + 249 Arg-Ser (AGG-AGT) – H/H
ID-098 + Poor + T/N + – – Wild-type + Y/H
ID-099 + Poor + T/N + – – Wild-type + H/H
ID-100 + Moderate + T/N + – + 249 Arg-Ser (AGG-AGT) – Y/H
ID-106 + Moderate + – – – Wild type + H/H
ID-107 + Poor + N+ – – Wild type + Y/Y
ID-109 – Poor + N + – + 249 Arg-Ser (AGG-AGT) – Y/H
ID-121 + Moderate + N + + – 266 Gly-Arg (GGA-CGA) + Y/Y
Total (n = 10) 6 10 8 1 4 5 5 4H/H, 4 Y/H
Qidong
94–18 + Poor + N + – + Wild type + Y/Y
94–20 + Moderate + T/N + – + 249 Arg-Ser (AGG-AGT) + Y/Y
94–21 – Moderate + – – + Wild type + H/H
94–24 – Poor + N + – + 249 Arg-Ser (AGG-AGT) – Y/H
94–25 + Moderate + N + – – 249 Arg-Ser (AGG-AGT) – Y/Y
94–28 + Poor + N + – + 249 Arg-Ser (AGG-AGT) + Y/Y
95–2 – Poor + – – + 249 Arg-Ser (AGG-AGT) – Y/H
95–3 + Poor + N + + – Wild type + Y/Y
95–4 + Poor + – – + 249 Arg-Ser (AGG-AGT) + H/H
95–6 + Moderate + N + – – Wild type + Y/Y
95–7 + Moderate + N + – + Wild type + Y/H
95–8 + Moderate + T/N + – + 249 Arg-Ser (AGG-AGT) + Y/Y
95–9 + Moderate + N + – – Wild type – H/H
95–12 + Moderate + T/N + – – Wild type + Y/Y
Total (n = 14) 11 14 11 1 9 7 10 3 H/H, 3 Y/H
aT = tumour; N = non-tumour. bNull phenotype denotes deletion of exons 4–5. cH = amino acid histidine at position 114 (a polymorphism with a less active
enzyme), Y = tyrosine (wild-type enzyme).T transversion at codon 249, position 3 (substitution of amino acid
arginine with serine, Figure 2), indicative of aflatoxin exposure.
The remaining two HCCs from Shanghai had point mutations with
a A to T transversion at codon 174, position 1 (substitution of
glycine with arginine) and a G to C transversion at codon 266,
position 1 (substitution of arginine with tryptophan). No germline
p53 mutations were present.
Fifty-four per cent (13/24) of HCCs showed nuclear staining
by p53 immunohistochemistry (Table 1), including 83% (10/12)
of HCCs with a p53 mutation and 25% (3/12) with no mutation
identified in exons 2–9 of the p53 gene (P = 0.01, odds ratio (OR)
15, 95% confidence interval (CI) 1.5 and 190).
LOH of chromosome 17 p was present in 70% (17/24) of HCCs.
17p LOH was present in 67% (8/12) of HCCs with a p53 mutation,
75% (9/12) without an identified p53 mutation, 67% (8/12) with
positive p53 immunohistochemistry and 75% (9/12) with negative
p53 immunohistochemistry (Figure 2). Twenty-nine per cent
(7/24) of HCCs showed 17p LOH without either p53 mutation or
positive immunohistochemistry, but no case with an identified p53
mutation lacked both p53 overexpression and 17p loss.
Microsatellite instability and LOH of chromosomes 1p,
4q, 13q and 16q
DNA replication errors (RER, microsatellite instability), indica-
tive of alteration of mismatch repair genes, was not present in
these HCCs. LOH of chromosome 1p was present in 46% (11/24)
of patients (Table 2, Figure 3). The telomeric markers D1S160,
D1S170 and D1S186 showed allelic loss in 44%, 40% and 50% of
patients with informative loci, respectively, but the centromeric
marker AMY2B did not show any allelic loss. LOH of chromo-
some 4q was present in 50% (12/24) of HCCs with informative
loci (Figure 4). Eighty-three per cent (10/12) of these HCCs
showed loss of two or more markers indicating a broad area of 4q
deletion and five of these showed retention of heterozygosity in an
intervening marker. LOH of chromosome 13q between the loci
13q12.3 and 13q21.1 was present in 38% (9/24) of HCCs, and
LOH of chromosome 16q between 16q12.1 and 16q24.2 was
present in 42% (10/24) of HCCs. Fractional allelic loss (FAL)
ranged from 0% to 91% with a median of 32%.
LOH of chromosome 4q was present in 75% (9/12) of HCCs
with a p53 gene mutation, but in only 25% (3/12) of HCCs without
a p53 gene mutation (Figure 3; P = 0.01, OR 9, 95% CI 1.1 and
84.6). Seven of the HCCs with 4q loss had the aflatoxin-associated
G–T transversion at codon 249, position 3. No association of afla-
toxin-modifying enzymes with loss of chromosomal arms or
concordant losses of chromosomal arms were identified.
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Figure 2 Sequence of p53 gene, exon 7, showing a G to T transversion at
codon 249 (substitution of amino acid arginine with serine) in a hepatocellular
carcinoma. This mutation is frequent in hepatocellular carcinomas from high
aflatoxin exposure areas
Figure 3 Mutation of p53 gene and loss of heterozygosity (LOH) of chromosomes 1p, 4q, 13q, 16q and 17p. Loss of chromosome 4q is present in 75% of
hepatocellular carcinomas with a p53 gene mutationDISCUSSION
We studied HCCs from Qidong and Shanghai in the People’s
Republic of China, regions with a high and an intermediate expo-
sure to aflatoxin respectively. All patients had prior exposure to
HBV as demonstrated by amplification of HBsAg and HbxAg, by
PCR from all cases, and immunohistochemical demonstration of
HBsAg in non-neoplastic liver in 79% of patient samples.
Histopathological evidence of chronic hepatitis was present in all
cases and cirrhosis in 71% of cases. HCV was not involved in the
pathogenesis of HCC in our cases, as judged by negative immuno-
histochemistry in all cases. There was also increased frequency of
GSTM1 null phenotype in these patients, corroborating a previous
report of an increased incidence of HCCs in patients with a null
phenotype, but no statistically significant association was found for
previously characterized mutation in epoxide hydrolase (McGlynn
et al, 1995). These findings confirm previous observations that
HBV infection, aflatoxin exposure, and GSTM1 are key players in
the aetiology of HCC in this area of the world.
Alteration of p53 was present in 95% of HCCs in our study as
demonstrated by sequencing in 50% of HCCs, positive immuno-
histochemistry in 54% and LOH of 17p in 70%. A similar
frequency of 17p loss has been reported previously (Yumoto et al,
1995). A mis-sense mutation with replacement of arginine by
serine at codon 249 has been reported previously in HCCs from
Qidong, Shanghai and other geographical areas where aflatoxin
and HBV are present (Bressac et al, 1991; Hsu et al, 1991; Ozturk
et al, 1991; Coursaget et al, 1993). LOH of 17 p without identified
p53 gene mutation or positive p53 immunohistochemistry was
present in 29% of HCCs in our study. HCCs developing in chronic
HBV infection with functional inactivation of wild-type p53 by
binding to HBxAg, as demonstrated in primary HCCs and in a
transgenic mouse model (Henkler et al, 1995; Ueda et al, 1995;
Greenblatt et al, 1997), could explain some of our cases.
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Figure 4 Loss of heterozygosity of chromosome 4q of two tumours (IC-221 and 95-2), using three different microsatellite markers (D4S395, D4S411 and
D4S415). N = normal, T = tumour. Arrowheads indicates loss of a band in a tumour lane present in the normal lane
Table 2 LOH of microsatellite markers in HCC
Microsatellite Chromosomal LOH/ Informative/
marker location informative (%) total (%)
D1S160 1p36.2 44 (4/9) 38 (9/24)
D1S170 1p36.2 40 (4/10) 42 (10/24)
D1S186 1p32.2 50 (6/12) 50 (12/24)
AMY2B 1p21 0 (0/14) 58 (14/24)
D4S395 4q12–13 53 (6/17) 71 (17/24)
D4S411 4q23–25 47 (7/15) 63 (15/24)
D4S427 4q26–28 53 (8/15) 63 (15/24)
D4S422 4q28 36 (4/11) 46 (11/24)
D4S415 4q32 57 (8/14) 58 (14/24)
D13S260 13q12.3 14 (2/14) 58 (14/24)
D13S126 13q14.1–14.3 44 (4/9) 28 (9/24)
D13S172 13q14.3–21.1 30 (3/10) 42 (10/24)
D13S227 13q14.3–21.1 56 (5/9) 38 (9/24)
D13S270 13q14.3–21.1 30 (3/10) 42 (10/24)
D16S419 16q12.1 20 (2/10) 42 (10/24)
D16S503 16q21 33 (3/9) 38 (9/24)
D16S512 16q22.1 50 (6/12) 50 (12/24)
D16S515 16 q 35 (6/17) 71 (17/24)
D16S516 16q24.1 33 (3/9) 39 (9/24)
D16S402 16q24.2 38 (6/16) 67 (16/24)
D17S1176 17p13.1 59 (10/17) 71 (17/24)
TP53 17p13.1 64 (7/11) 46 (11/24)
VNTR 17 p 39 (7/18) 75 (18/24)
D17S520 17p12 53 (9/17) 71 (17/24)No HCC in our study had microsatellite instability (allelic shifts
in more than 40% of microsatellite markers). This corroborates a
previous study which reported allelic shifts in 0 to 14% (mean of
1%) of microsatellite markers in 100 HCCs using 295 microsatel-
lite markers (Boige et al, 1997).
LOH of chromosome 1p was present in 46% of HCCs in our
study. Trisomy chromosome 1, and deletions and translocations of
the short arm of chromosome 1 (1p) are frequent in HCCs by cyto-
genetic analysis (Simon et al, 1991; Chen et al, 1996), in situ
hybridization (Nasarek et al, 1995), RFLP (Simon et al, 1991) and
microsatellite analysis (Yeh et al, 1994; Kuroki et al, 1995a,
1995b). LOH of chromosome 1p is an early event in hepatocar-
cinogenesis as evidenced by allelic loss in early or well-differenti-
ated HCCs without loss of other chromosomal arms frequently lost
in HCCs (Kuroki et al, 1995b). We observed loss of the telomeric
portion of 1p, which is consistent with the previous study (Yeh et
al, 1994). Allelic loss of 1p is also reported in other malignant
tumours, such as neuroblastoma (Weith et al, 1989), colon cancer
(Leister et al, 1990), breast cancer (Devilee et al, 1991) and malig-
nant melanoma (Dracopoli et al, 1989).
LOH of 13q was present in 38% of HCCs in our study with
microsatellite markers mapped to a region between 13q12.3 and
13q21.1. This region has been previously shown to include two
important loci, the retinoblastoma and BRCA2 genes, and alter-
ations of these genes are present in a subset of HCCs (Zhang et al,
1994; Kuroki et al, 1995a; Yumoto et al, 1995; Katagiri et al, 1996).
LOH of 16q was present in 42% of HCCs in our study. Loss of
16q is a late event in hepatocarcinogenesis and is more frequent in
HCCs of poor differentiation, of larger size, and with metastasis
(Tsuda et al, 1990; Yumoto et al, 1995). Reduced expression of the E-
cadherin gene is associated with LOH of 16q (Slagle et al, 1993).
LOH of 4q was present in 50% of HCCs in the present study,
42–77% of HCCs in previous studies (Buetow et al, 1989;
Fujimori et al, 1991; Yumoto et al, 1995; Yeh et al, 1996; Boige et
al, 1997; Marchio et al, 1997; Nagai et al, 1997) and in a human
hepatoma cell line (Urano et al, 1991). This loss of chromosome
4q maps to at least two regions (4q12–21, 4q22–24 and possibly
an additional telomeric location) and may represent one or more
tumour suppressor genes (Yeh et al, 1996; Boige et al, 1997;
Marchio et al, 1997; Nagai et al, 1997). Of note, in the present
study, five of ten HCCs with loss of two or more markers had
retention of an intervening marker suggesting loss of two separate
loci on chromosome 4q. Loss of 4q was associated with an
elevated serum a-fetoprotein in HCCs patients from Taiwan (Yeh
et al, 1996). Loss of chromosome 4q has also been reported in
head and neck squamous cell carcinoma (Perhouse et al, 1997),
cervical carcinoma (Mitra et al, 1994; Hampton et al, 1996),
bladder carcinoma (Polascik et al, 1995), oesophageal and gastric
cardia adenocarcinomas (Hammoud et al, 1996; Gleeson et al,
1997) and Hodgkin’s disease (Dohner et al, 1992).
Introduction of a normal human chromosome 4 into immortal
cell lines results in loss of proliferation and reversal of the
immortal phenotype (Ning et al, 1991). A gene in the human chro-
mosome 4q25–34 can complement the inability of a Chinese
hamster mutant cell line to inhibit DNA synthesis, without altering
cell survival and chromosomal stability after irradiation (Verhaegh
et al, 1995). A potential candidate for a tumour suppressor gene is
PTPN13, a Fas-associated protein tyrosine phosphatase which
binds to a negative regulatory domain in FAS protein and inhibits
FAS-induced apoptosis (Inazawa et al, 1996). This gene is located
at 4q21.3 which is adjacent to marker D4S411 used in this study.
Other potential candidates are caspase 3 (CPP-32/apopain) and
caspase 6 (Mch2), mammalian homologues of Ced-3 gene, and are
responsible for cleavage and inactivation of key homeostatic
protein during apoptosis (Nasir et al, 1997). The caspase 3 gene is
located at 4q34 which is telomeric to marker D4S415, and the
caspase 6 gene is located at 4q24–25. The loss of a gene(s)
involved in apoptosis may complement the effects of p53 muta-
tion, especially aflatoxin-associated p53 mutation as has been
demonstrated in vitro (Ponchel et al, 1994; Dumenco et al, 1995).
Transfection of a mutant p53 gene with serine at the codon 249 in
a human p53-deficient hepatoma cell line induces increased in
vitro survival and mitotic activity but has no effect on tumori-
genicity in nude mice or apoptosis (Ponchel et al, 1994). Similarly,
transfection of a mutant murine p53 gene coding for serine at the
codon 246 (equivalent to human codon 249) in a murine hepato-
cyte cell line resulted in an increase in colony number and size,
and improved growth in serum free conditions but did not cause
transformation (Dumenco et al, 1995).
Fractional allelic loss (FAL) in our study ranged from 0% to
91% with a median of 32%. Two previous studies, using 195 and
275 microsatellite markers on all the chromosomes, have demon-
strated less frequent FAL in HCCs with a range of 0–40% and
0–42%, respectively, and mean of 15% and 12% (Boige et al,
1997; Nagai et al, 1997). The higher frequency of FAL in our
study reflects evaluation of markers on chromosomal arms which
are preferentially lost in hepatocarcinogenesis.
The evaluation of multiple alterations in our study permitted us
to identify interactions among environmental and genetic events.
We found that LOH of 4 q was present in 75% of HCCs with a p53
gene mutation, but in only 25% of HCCs without a p53 gene muta-
tion (P = 0.01). The association of 4q loss with p53 mutation is not
explained by generalized allelic loses after p53 inactivation
because 1p, 13q and 16q losses were not increased in HCC with
p53 mutation. Additional studies are needed to see if this
concerted loss of 4q in HCCs from high incidence areas with a p53
mutation is also present in HCCs from low incidence areas.
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